G01N 2800/164
Retinal disorders
Official title: Retinal disorders, e.g. retinopathy
G01N2800/164 (Retinal disorders) appears on 80 US grants and 214 published applications in this corpus.
Search patents in G01N- Granted patents
- 80
- Published applications
- 214
- Assignees
- 132
- Inventors
- 387
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 3 |
| 2003 | 0 | 4 |
| 2004 | 1 | 2 |
| 2005 | 0 | 4 |
| 2006 | 2 | 10 |
| 2007 | 0 | 7 |
| 2008 | 3 | 9 |
| 2009 | 0 | 13 |
| 2010 | 4 | 11 |
| 2011 | 5 | 16 |
| 2012 | 6 | 15 |
| 2013 | 5 | 2 |
| 2014 | 2 | 10 |
| 2015 | 3 | 4 |
| 2016 | 5 | 9 |
| 2017 | 3 | 6 |
| 2018 | 5 | 13 |
| 2019 | 4 | 8 |
| 2020 | 3 | 12 |
| 2021 | 6 | 9 |
| 2022 | 6 | 15 |
| 2023 | 6 | 11 |
| 2024 | 1 | 8 |
| 2025 | 6 | 8 |
| 2026 | 4 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition15 Sep 2026US 12,735,707 B2Massachusetts Eye and Ear Infirmary
- Anti-VEGF single-domain antibody and use thereof16 Jun 2026US 12,655,204 B2Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Prediction of the content of omega-3 polyunsaturated fatty acids in the retina by measuring 7 cholesterol ester molecules7 Apr 2026US 12,596,127 B2Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Metabolic rescue of retinal degeneration24 Feb 2026US 12,558,336 B2The Board of Trustees of the Leland Stanford Junior University
- Semaphorin 3A antibodies and uses thereof30 Dec 2025US 12,509,512 B2Ramot at Tel-Aviv University Ltd.
- Use of extracellular vesicles as biomarkers for age-related macular degeneration27 Aug 2026US 2026/0250766 A1Research Foundation of the City University of New York
- Methods for monitoring molecular biomarkers for aging and disease27 Aug 2026US 2026/0251662 A9The Board of Trustees of the Leland Stanford Junior University
- Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders16 Jul 2026US 2026/0199341 A1Children's Medical Center Corporation
- Methods for selecting and treating patients with retinal disease based on complement pathway hyperactivity2 Jul 2026US 2026/0185992 A1Oak Bay Biosciences Inc.
- Composition for diagnosing age-related macular degeneration using proteomic analysis and biomarkers, method for providing information for diagnosing agerelated macular degeneration, and method for screening substances for treating agerelated macular degeneration11 Jun 2026US 2026/0159888 A1Julia Laboratory Inc.
Most cited
By later US patents
- Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration46US 7,816,497 B2University of Kentucky · 2010
- Diagnostics and the therapeutics for macular degeneration33US 7,108,982 B1University of Iowa Research Foundation · 2006
- Diagnostics and therapeutics for macular degeneration-related disorders28US 7,351,524 B2University of Iowa Research Foundation · 2008
- Diagnostics and therapeutics for macular degeneration-related disorders23US 7,011,952 B2University of Iowa Research Foundation · 2006
- Complement assays and uses thereof18US 9,291,622 B2Apellis Pharmaceuticals, Inc. · 2016